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Background: Biliary brush cytology is the standard method of evaluating biliary strictures, but is insensitive at detecting
malignancy. In pancreaticobiliary cancer minichromosome maintenance replication proteins (MCM 2–7) are dysregulated in the
biliary epithelium and MCM5 levels are elevated in bile samples. This study aimed to validate an immunocolorimetric ELISA assay
for MCM5 as a pancreaticobiliary cancer biomarker in biliary brush samples.
Methods: Biliary brush specimens were collected prospectively at ERCP from patients with a biliary stricture. Collected samples
were frozen at  80 1C. The supernatant was washed and lysed cells incubated with HRP-labelled anti-MCM5 mouse monoclonal
antibody. Test positivity was determined by optical density absorbance. Patients underwent biliary brush cytology or additional
investigations as per clinical routine.
Results: Ninety-seven patients were included in the study; 50 had malignant strictures. Median age was 65 years (range 21–94) and
51 were male. Compared with final diagnosis the MCM5 assay had a sensitivity for malignancy of 65.4% compared with 25.0% for
cytology. In the 72 patients with paired MCM5 assay and biliary brush cytology, MCM5 demonstrated an improved sensitivity
(55.6% vs 25.0%; P¼ 0.0002) for the detection of malignancy.
Conclusions: Minichromosome maintenance replication protein5 is a more sensitive indicator of pancreaticobiliary malignancy
than standard biliary brush cytology.
Being able to diagnose pancreatic and biliary tract cancer
with a single investigation and at an early stage when curative
treatment is feasible remains a significant clinical challenge.
Current diagnostic modalities such as serum tumour markers,
cross-sectional imaging and cholangiography do not have sufficient
sensitivity to diagnose malignancy when used alone or in
combination, especially in the early stages of malignancy when
the lesion is small (Lee, 2006; Kalaitzakis et al, 2011). Cytological or
histological confirmation is almost always required prior to
surgical resection or treatment and are usually acquired from
biliary strictures or associated masses, commonly by brush
cytology or endobiliary biopsy (De Bellis et al, 2002). Although
these techniques do not compromise resection margins in
potentially resectable cases and have a high specificity (96–100%)
for malignancy, sensitivity remains low (9–57%) and patients
frequently have to undergo multiple procedures to obtain a final
diagnosis (De Bellis et al, 2002; Harewood et al, 2004; Moreno
Luna et al, 2006).
The poor sensitivity of cytology is multifactorial, biliary tract
and pancreatic cancers typically have a desmoplastic component
and specimens are often paucicellular in nature. In addition
obtaining and interpreting cytological specimens can be operator-
and observer-dependent. Therefore there has been a growing
interest in developing adjunctive tests such as fluorescence in situ
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hybridisation (FISH) and evaluating novel procedures, such as
cholangioscopy and confocal endomicroscopy, to improve the
detection of pancreaticobiliary malignancy (Kalaitzakis et al, 2012;
Keane et al, 2013). A recent meta-analysis found the sensitivity of
endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
to be 74.2%, FISH 54.2%, serum CA19-9 69.3% and a K-ras
mutation 47.0% (Burnett et al, 2014). Randomised controlled trials
are ongoing to determine if multiple endobiliary brushings or
multimodal stricture assessment including cholangioscopy and
FISH are the optimal approach for the assessment of indeterminate
biliary strictures (Cote et al, 2015).
The initiation of DNA replication is the final part of growth
regulation, located downstream of all growth regulatory pathways
(Williams and Stoeber, 1999). Minichromosome maintenance
proteins (MCM2–7) participate in the assembly of prereplicative
complexes, which initiate DNA synthesis. All six MCM proteins
are essential for replication and are present in all phases of
the proliferative cell cycle but are tightly downregulated in the
quiescent, terminally differentiated ‘out-of-cycle’ states. The
presence of one MCM protein reflects the presence of the other
five as all six are loaded together onto DNA as a heterohexamer on
exit from metaphase (Blow and Hodgson, 2002). We have shown
that these biomarkers detect, in addition to actively proliferating
malignant cells, those with growth potential, that is, premalignant
cells, as dysregulation in MCM proteins is an early event in
epithelial carcinogenesis (Freeman et al, 1999; Stoeber et al, 2001).
Moreover, we have demonstrated the utility of these novel
biomarkers of growth as diagnostic markers in a range of cancers
including biliary tract and pancreatic cancer (Wharton et al, 2001;
Williams and Stoeber, 2007; Ayaru et al, 2008; Loddo et al, 2009).
STUDY AIM
The aim of the study was to validate a newly developed
immunocolorimetric ELISA test for the MCM5 protein in samples
obtained by biliary brush cytology.
MATERIALS AND METHODS
Setting. A large regional Hepatopancreaticobiliary (HPB) centre.
Endoscopic procedures were performed at University College
London Hospital (UCLH) or the Royal Free Hospital (RFH),
London.
Design. The design was a Prospective Cohort Study.
Ethical approval. The study was approved by the Joint UCLH/
UCL ethical committee and all patients gave written informed
consent (NRES: 06/Q0512/106).
Inclusion criteria. Patients 418 who underwent a clinically
indicated endoscopic retrograde cholangiopancreatography
(ERCP) between 01 June 2011 and 30 June 2015.
Clinical data. For each patient recruited, the electronic medical
records were reviewed and information was recorded in an
electronic spreadsheet. Data were recorded from the Pathology
(CoPath histology database, Sunquest, Tucson, AZ, USA), Endo-
scopy (GI reporting tool, Unisoft Medical Systems, Enfield, UK)
and Imaging (PACS: picture archiving and communication system,
GE Healthcare, Pollards Wood, UK) database systems. Data
collected included demographic information (age, sex and hospital
number), history of acute or chronic pancreatitis or malignancy,
family history of pancreatic cancer or relevant clinical syndrome.
Cross-sectional imaging (computed tomography (CT) and/or
magnetic resonance cholangiopancreatography (MRCP)) features
were recorded. Details of the ERCP procedure along with cytology
and histology results were recorded. For patients referred for
surgery, date of the operation, type of resection and final histology
were recorded. Length of follow-up was calculated from first
procedure to last clinic appointment attended, or date of clinic
discharge, or death.
A diagnosis of malignancy was made by surgical resection,
positive histological biopsy or positive cytology where available, or
evidence of disease progression on imaging when not. Benign
disease was established by negative pathology and a median of 14
(range 0–49) months clinical follow-up.
Patients. Between June 2011 and June 2015, 102 patients with an
established or indeterminate biliary stricture were invited to
participate in the study. Established patients were defined as those
with an existing diagnosis for their biliary stricture who were
having a repeat ERCP for therapeutic reasons such as stent change
and consented to participate in the study. Patients with an
indeterminate biliary stricture included patients with a stricture on
cross-sectional imaging; 41% (28 out of 68) had at least one ERCP
with biliary brushing prior to entering the study (11 had one prior
ERCP, 14 two prior ERCPs, 3 three prior ERCPs and in one case
four prior ERCPs before entering the study).
Five patients were excluded as there was insufficient sample
remaining to perform the MCM5 test following prior investiga-
tions. Ninety-seven patients were included in the final analysis.
Procedures
Endoscopic retrograde cholangiopancreatography. The proce-
dures were performed under general anaesthesia or conscious
sedation with midazolam and fentanyl. All ERCPs were performed
by one of five experienced endoscopists using a standard
therapeutic duodenoscope (JF; Olympus, Southend-on-Sea, UK).
All procedures were performed in the endoscopy unit with
fluoroscopy. Biliary brush cytology was obtained following
cholangiography using a wire-guided sheathed cytology brush
(Combocath, Microinvasive; Boston Scientific, Notick, MA, USA),
advanced across the stricture several times before being resheathed
and the sheathed brush withdrawn from the endoscope. In this
study, tissue acquisition was performed before any therapy
(stricture dilation, stenting and so on.) In 72 cases, where clinically
indicated, a single biliary brush sample was taken for routine
cytology before another biliary brush sample was taken for the
MCM5 assay.
The clinical cytology specimen was then transferred immedi-
ately to glass slides by smearing the cellular material from the
brush directly onto two slides. These were fixed and later stained
for malignant cells using the standard Papanicolaou technique.
Brush cytology samples were analysed by expert cytopathologists
within the context of a multidisciplinary cancer review meeting.
Cytology was classified as malignant or no definitive evidence of
malignancy (highly suspicious, dysplastic, atypia, inflammatory
and normal). Endobiliary biopsy was obtained using standard
endoscopic biopsy forceps. Following ERCP all patients were
observed for 4 h in the recovery area prior to discharge, or
admitted to hospital if further observation was deemed clinically
necessary.
Biliary brush collection and storage for MCM5 assay analysis.
After removal of the biliary brush from the working channel of the
endoscope the brush was advanced out of the sheath, cut and
placed into a storage buffer (Varleigh Dx (UK) Ltd, London, UK),
which contained one complete mini EDTA-free protease inhibitor
cocktail tablet (Roche Diagnostics Ltd, Lewes, East Sussex, UK) per
10ml of buffer. The sample was gently agitated before being
rapidly frozen to  80 1C within 4 h of the procedure.
In vitro diagnostic assay development and validation. In
conjunction with a commercial partner (Varleigh Dx (UK) Ltd)
and under licence from the Cancer Research United Kingdom
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(CRUK) licencing group Cancer Research Technologies (CRT), a
diagnostic MCM5 ELISA assay was developed in conformity with
the requirements of the IVD Directive EC 98/79/EC. Validation
studies were designed to test required aspects of assay performance
including clinical performance, assay precision, interference, cross
reactivity and stability. The pathway for translation of this assay
from a research immunofluorometric method to an IVD
immunocolorimetric method is shown in Figure 1.
Antibody development. Monoclonal antibodies (MAbs) 12A7
and 4B4, directed against non-overlapping epitopes, were raised
against His-tagged human MCM5 protein and were protein
A-purified from hybridoma supernatants as described previously
(Stoeber et al, 2002). For use in the ELISA assay the
protein A-purified MAb 12A7 was labelled with horseradish
peroxidase using conventional conjugation techniques, whereas
capture antibody 4B4 was adsorbed to the surface of microtitre
plate wells.
Clinical validation studies. Ninety-seven patients with complete
clinical follow-up diagnosis and adequate sample lysate
volume following protein extraction were subject to the MCM5
ELISA. About 51 were performed in duplicate as per the
manufacturer’s instructions. The assay was controlled using
(a) lysis buffer as the blank representing the cell lysate matrix
and (b) recombinant MCM5 antigen-positive analyte control
(concentration B0.60 ngml 1). The assay was further controlled
using a calibrator of recombinant MCM5 antigen (batch specific
calibrator concentration 0.29 ngml 1). Optical density (OD)
measurements were recorded for all samples and controls tested.
On completion of the study, patient data and the MCM5 ELISA
results were compared with biliary brushing cytology results, where
available, and final clinical diagnosis after follow-up.
Assay precision studies. Precision studies were conducted utilis-
ing recombinant MCM5 antigen. A 12-day study was conducted
using three reagent kit lots (12 runs with each reagent lot) and four
replicates of each control sample per run.
Assay cross reactivity and interference studies
Cross reactivity. In order to ensure specificity of the ELISA for the
MCM5 target protein cross reactivity studies were performed
against other members of the MCM family (MCM2–7). Each
MCM protein was tested in duplicate over the range of
concentrations 0.05–100 ngml 1.
Interferences. During ERCP iodine-based contrast media (Omni-
paque) was used to delineate the biliary tract. In our study we
tested to see if Omnipaque was present in test samples at
concentrations comparable to residual levels, which may be carried
over into the test specimen and show interference in the assay.
A worst case theoretical residual concentration of 50 mg organic
iodine per ml from Omnipaque 300 (647mgml 1 iohexol/300mg
organic iodine per ml) was established and a dilution series created
50% either side of this concentration (25, 50 and 75mg iodine per
ml) in both positive and negative MCM5 solutions, measuring five
replicates of each and recording the absorbance measurements at
450 nm for all samples and controls.
Assay stability studies. In order to ensure preliminary stability of the
working assay, manufactured components were assembled into kits and
stability of the assay reagents were assessed by repeat measurements of
a panel of samples at monthly intervals using reagents stored at 2–8 1C,
using an unopened kit at each time point and also at 2 weekly intervals
using a kit opened at t¼ 0. The absorbance measurements at 450nm
were recorded for all samples and controls tested.
Data analysis. Statistical package for Social Sciences for Windows,
version 21.0 (SPSS Inc., Chicago, IL, USA) was used to perform all
statistical analyses. Associations between various clinical and radio-
graphic characteristics were evaluated using a 2-sample t-test for
continuous variables and a 5% level was used to indicate significance.
The sensitivity for biliary brush cytology was compared with that of
the immunofluorometric MCM5 test using McNemar’s test for paired
proportions. Sensitivity and specificity characteristics of the MCM5
test for the detection of malignancy were presented as a receiver
operating characteristics (ROC) curve. The area under the nonpara-
metric ROC curve was used to assess the overall accuracy of the test.
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Figure 1. Stages of development of the MCM5 immunocolorimetric ELISA assay.
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RESULTS
Assay precision studies. A precision profile was generated from a
single assay of seven replicates of recombinant MCM5 antigen
standards on each of three reagent lots. From this precision profile,
CV at the cut-off concentration of 0.11 ngml 1 was calculated to
be 13.2%. The Total CV for Calibrator OD450 was found to be
5.7% The Total CV for Positive Control OD450 was found to
be 7.0%.
Assay cross reactivity and interference studies
Interference studies. The presence of iohexol and up to 75 mg
iodine per ml (the components of Omnipaque) in the lysis solution
had no significant effect on the test signal. The maximum effect of
iohexol was seen in a 0.6 ngml 1 MCM5-positive solution, when a
1.5% reduction in test signal was observed but this was still
insufficient to misclassify the test result.
Cross reactivity. No cross reactivity was observed for proteins
MCM2, 4, 6 and 7 and with percentage variationo1%. A marginal
cross reactivity measured at 5.2% was observed for MCM3. Both
measures were beneath the threshold of diagnostic impact.
Assay stability studies. No change in performance was observed
for the unopened kit after 7 months storage at 2–8 1C and for the
opened kit after 6 weeks storage at 2–8 1C.
Clinical validation studies: final MCM5 immunoassay perfor-
mance. Biliary brush samples were acquired from 97 procedures
performed on 94 patients (three patients had repeat MCM5
measurements at two different ERCPs). At recruitment to the
study, 29 patients had an established diagnosis, whereas 68 were
new referrals with an indeterminate stricture. Their final diagnoses
are outlined in Table 1. The median age of the patients was 65
years (21–94 years). About 51 were male and 46 were female.
Of the 50 patients with malignant disease the final diagnosis was
made by brush cytology (n¼ 16), EUS-FNA or biopsy (n¼ 3),
endoscopic or endobiliary biopsy (n¼ 3), cholangioscopy and
biopsy (n¼ 1), percutaneous pancreatic biopsy (n¼ 1), percuta-
neous liver biopsy of metastatic disease (n¼ 4), surgical resection
(n¼ 7), intraoperative pancreatic biopsy (n¼ 2) or clinical course
(n¼ 13). Patients underwent a mean of 1.9 attempts at tissue
acquisition (range 1–8) before malignancy was confirmed. Benign
disease was confirmed by negative pathology during a median of
14 (range 0–49) months follow-up.
The performance of the MCM5 ELISA assay as an in vitro
diagnostic test for pancreaticobiliary malignancy in patients with
indeterminate strictures is shown as a ROC curve (Figure 2). The
test discriminated with high accuracy between patients with and
without malignancy, as demonstrated by an area under the curve of
0.785 (95% CI 0.631–0.939), which was significantly larger than the
area predicted by the null hypothesis (Pp0.0001).
When compared directly with final diagnosis the MCM5 assay
had a sensitivity and specificity of 65.38% and 77.78%, respectively.
In comparison, biliary brush cytology had a sensitivity and
specificity of 25.0% and 100%, respectively (Table 2, Figure 3).
Differences in test performance were observed in patients with
certain stricture subtypes, in particular false-positive results were
seen in patients with IgG4-related disease, chronic pancreatitis and
primary sclerosing cholangitis (Table 3). In the 72 patients with
paired MCM5 levels and biliary brush samples, MCM5 demon-
strated an improved sensitivity when compared against biliary
brush cytology (55.56 vs 25.00%; P¼ 0.0002) for the detection of
malignancy. No difference was seen between the sensitivity of the
MCM5 assay and cytology that included cancer and high-grade
dysplasia (55.56 vs 55.56%; Figure 3).
Cost and turnaround time analysis for MCM5 immunoassay.
We estimate that a diagnostic MCM5 ELISA assay would be
comparable to a non-gynaecological diagnostic cytology sample,
inclusive of laboratory preparation, overheads and pathologist
interpretation.
We envisage that in clinical practice the MCM5 assay would be
performed on a weekly basis as a batched assay, inclusive of a LIMS
interfaced report into the hospital electronic patient record.
Laboratory turnaround time and cost efficiencies would be seen
based on testing economies of scale. As multiple centres came
online the assay could be run at least twice per week, with a
turnaround time of 72 h from receipt of sample.
DISCUSSION
In patients who present with indeterminate biliary strictures,
biliary brush cytology remains the most commonly used test to
distinguish benign and malignant disease. The technique offers the
Table 1. Final diagnosis
Final diagnosis
Established
diagnosis (n¼29)
New indeterminate
stricture (n¼68)
Total
(n¼97)
Benign (n¼47)
Primary sclerosing cholangitis 7 5 12
IgG4-related disease 6 5 11
Intraductal polyp with low-grade dysplasia 0 1 1
Benign papillary fibrosis / stone-related strictures 3 6 9
Post-surgical stricture (following liver transplant (n¼ 1) or laparoscopic cholecystectomy (n¼1)) 2 0 2
Ischaemic stricture post hepatic artery thrombosis following emergency embolisation 0 1 1
Chronic pancreatitis 3 5 8
Benign cystic lesion of the pancreas 0 2 2
Caroli disease 0 1 1
Malignant (n¼50)
Pancreatic ductal adenocarcinoma 1 23 24
Diffuse large B-cell lymphoma of the pancreas 0 1 1
Biliary tract cancer 4 13 17
Ampullary adenocarcinoma 0 3 3
Colorectal cancer with liver metastases 1 0 1
Mediastinal non Hodgkin’s lymphoma 1 0 1
Metastatic breast cancer 1 0 1
Hepatocellular carcinoma 0 1 1
Midgut neuroendocrine tumour 0 1 1
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clinician almost definitive diagnostic certainty when positive for
malignancy (specificity 96–100%) but remains unreliable for
detecting malignancy (sensitivity 9–57%; De Bellis et al, 2002;
Harewood et al, 2004; Moreno Luna et al, 2006).
We have previously shown that the upregulation of the MCM5
protein is a reliable biomarker for malignancy in tissue samples
from the bladder, prostate, oesophagus and pancreaticobiliary tract
(Stoeber et al, 2002; Williams et al, 2004; Ayaru et al, 2008). In a
Table 2. Comparison of sensitivity, specificity, NPV and PPV for biliary brush cytology, MCM5 assay, a combination of cytology
and MCM5 assay and the MCM5 assay excluding patients with IgG4-related disease
Patient group
Group
size (N) Sensitivity (%) Specificity (%)
Positive predictive
value (%)
Negative predictive
value (%)
Biliary brush cytology 72 25.00 (12.12–42.20) 100.00 (90.26–100.00) 100.00 (66.37–100.00) 57.14 (44.05–69.54)
MCM5 assay 97 65.38 (50.91–78.03) 77.78 (62.91–88.80) 77.27 (62.16–88.53) 66.04 (51.73–78.48)
CytologyþMCM5 assay 72 64.71 (46.49–80.25) 78.95 (62.68–90.45) 73.33 (54.11–87.72) 71.43 (55.42–84.28)
MCM5 assay (excluding patients with IgG4-RD) 86 62.00 (47.17–75.35) 80.56 (63.98–91.81) 81.58 (65.67–92.26) 60.42 (45.27–74.23)
Abbreviations: IgG4-RD¼ IgG4-related disease; NPV¼ negative predictive value; PPV¼positive predictive value.
Sensitivity Specificity
Positive
predictive
value
Negative
predictive
value
Cytology – cancer (%) 25.00 100.00 100.00 57.14
Cytology – cancer &/or HGD (%) 55.56 100.00 100.00 69.23
MCM5 (%) 55.56 77.78 71.43 63.64
0.00
20.00
40.00
60.00
80.00
100.00
120.00
%
Figure 3. Comparison of sensitivity, specificity, NPV and PPV in patients with paired cytology and MCM5 biliary brush assay.
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Figure 2. ROC curve for patients with paired biliary brush cytology and MCM5 assay.
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previous study by our group it was shown that cell cycle proteins in
bile aspirates had a significantly superior diagnostic sensitivity for
malignancy than routine cytology (66 vs 20%; Ayaru et al, 2008).
Biliary brush samples are recognised to be significantly more
cellular than bile samples, so it was anticipated that samples
obtained via this method would be superior to bile alone. During
this validation study using biliary brush samples, a newly
developed MCM5 ELISA assay was shown to be superior for
detecting pancreaticobiliary malignancy over standard brush
cytology while maintaining a high specificity (sensitivity of
65.38% and specificity of 77.78%).
This study confirms that measurement of the MCM5 proteins
using a highly sensitivity ELISA assay is a robust method of
detecting upregulated MCM5 proteins in pancreaticobiliary
malignancy. Moreover, as these malignancies are associated with
different sets of genetic mutations leading to uncontrolled cell
proliferation, this study provides further evidence supporting the
hypothesis that the convergence point of growth regulatory
pathways that control cell proliferation is the initiation of genome
replication in which the MCM complex plays an essential part. The
expression of MCM5 in malignant biliary brush samples was
equivalent to bile aspirates (Ayaru et al, 2008), but lower than that
detected in urine and oesophageal aspirates obtained from patients
with bladder and oesophageal cancer (Stoeber et al, 2002; Williams
et al, 2004).
Importantly, assay performance was less accurate in certain
groups, and false-positive results were seen in patients with
inflammatory strictures secondary to IgG4-related disease, chronic
pancreatitis and primary sclerosing cholangitis. These conditions
are recognised to predispose individuals to pancreaticobiliary
cancer and to be particularly difficult to distinguish from
malignant disease using conventional diagnostic tests (Lazaridis
and Gores, 2005; Hamer and Feuerbach, 2006). Benign strictures
from bile duct stones, with or without cholangitis did express low
levels of MCM5 but median levels were below the detection limit of
the assay, reflecting low shedding of any reactive MCM5-positive
cells. This was similar to our previous data in patients with renal
calculi and oesophageal ulceration, where the test detected positive
cells in urine and luminal secretions, but at a magnitude below
that of patients with urothelial or oesophageal carcinoma (Stoeber
et al, 2002; Williams et al, 2004). This study using a MCM5
immunofluorometric assay validates previous finding in tissue and
bile aspirates in pancreaticobiliary cancer (Ayaru et al, 2008).
The molecular diagnosis of pancreaticobiliary malignancies has
been the subject of intensive investigation (Gress, 2004), but to date
very few of the tests developed have been incorporated into routine
clinical practice. A recent study of FISH to detect chromosomal
abnormalities in biliary brush cytology samples demonstrated
results comparable to our study with a sensitivity of 59–70% and
specificity of 86–100% for the diagnosis of pancreaticobiliary
malignancy compared with a sensitivity of 4–20% for conventional
brush cytology (Moreno Luna et al, 2006). Increasingly multimodal
investigation of biliary strictures is advocated to enable a rapid
and accurate diagnosis, so patients can commence treatment
promptly (Cote et al, 2015). However cholangioscopy, confocal
endomicrosopy (Keane et al, 2013), endoscopic ultrasound and in
room cytopathology (De Bellis et al, 2002) are usually only
available in specialist centres and, therefore, are only performed
once standard diagnostic methods have failed to establish a
definitive diagnosis. The advantage of this immunocolorimetric
ELISA assay is that it is based on biliary brush sampling and is
therefore technically easier to perform than the other methods
described and can be done at the same time as the first diagnostic
ERCP. The higher sensitivity of this test for malignancy is also
likely to improve the overall diagnostic accuracy of the first ERCP
procedure. It therefore has the potential to be easily incorporated
into future diagnostic pathways or multimodal methods of stricture
assessment.
This test also has the potential to be used in combination with
other standard investigations for hepatobiliary malignancy. Our
group has explored the utility of the MCM5 assay in detecting
malignancy in cystic lesions of the pancreas. Early data suggest that
it can detect malignancy in this setting with a sensitivity of 50%
and specificity of 73% (Keane et al, 2016). Guidelines on the
evaluation of biliary strictures increasingly advocate the use of
EUS-FNA to aid diagnosis, particularly in indeterminate lesions
with at least one unsuccessful attempt at tissue acquisition
(Anderson et al, 2013). Given the promising early results using
EUS-FNA in cystic lesions of the pancreas, there is the potential for
the MCM5 test to be developed in the setting of EUS-FNA of
pancreaticobiliary stricture assessment as well.
CONCLUSIONS
In conclusion, we have demonstrated that a rapid, sensitive and
specific immunocolorimetric ELISA for detection of MCM5 in
biliary brush samples is a robust diagnostic test for pancreatico-
biliary malignancy.
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Pancreatic ductal adenocarcinoma 24 0.6915 (0.024–4.792) 0/24 9/24
Biliary tract cancer 17 1.111 (0.007–24.795) 0/17 6/17
Ampullary adenocarcinoma 3 0.393 (0.213–2.622) 0/3 2/3
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